Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in ...

The CDC's newly reconstituted Advisory Committee on Immunization Practices (ACIP) voted 5-2 in support of infants younger ...

Robert F. Kennedy Jr.’s vaccine advisory committee recommended Merck & Co.’s shot to prevent newborns from getting RSV, ...

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

Kennedy Jr.’s vaccine committee on Thursday voted to recommend a shot that protects babies against RSV, reports said. The ...